文献速递造血干细胞移植与细胞治疗

EGFL7调节内皮细胞减轻小鼠异基因骨髓移植后急性GVHD

Modulating endothelial cells with EGFL7 to diminish aGVHD after allogeneic bone marrow transplantation in mice.
PubMed 文献 · Blood Adv · 2022-01-01

急性移植物抗宿主病(aGVHD)是异基因造血干细胞移植(allo-HSCT)后第二常见死因。基于内皮细胞功能障碍参与aGVHD且EGFL7可抑制内皮细胞活化与T细胞迁移,本研究在小鼠aGVHD模型中给予重组EGFL7(rEGFL7),发现其减轻aGVHD严重程度、改善生存且不影响移植物抗白血病效应,并提高胸腺细胞及T、B、树突状细胞计数。

要点

  • rEGFL7在两种小鼠aGVHD模型中减轻aGVHD严重程度并改善生存。
  • rEGFL7不影响移植物抗白血病效应。
  • rEGFL7提高受体小鼠胸腺细胞及T、B、树突状细胞计数。

核心结论

  • 重组EGFL7治疗可减轻小鼠异基因骨髓移植后aGVHD严重程度和死亡率,且不影响移植物抗白血病效应。

研究设计与样本

  • 研究在两种小鼠aGVHD模型中给予重组EGFL7(rEGFL7)治疗,并与对照比较。

主要发现

  • rEGFL7治疗降低两种小鼠aGVHD模型的aGVHD严重程度并改善受体小鼠生存。
  • rEGFL7治疗不影响移植物抗白血病效应。
  • rEGFL7治疗提高受体小鼠胸腺细胞、T细胞、B细胞和树突状细胞计数。

临床怎么用

  • 本研究为概念验证,提示rEGFL7可能作为减轻allo-HSCT后aGVHD严重程度和死亡率的潜在策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (aGVHD) is the second most common cause of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT), underscoring the need for novel therapies. Based on previous work that endothelial cell dysfunction is present in aGVHD and that epidermal growth factor-like domain 7 (EGFL7) plays a significant role in decreasing inflammation by repressing endothelial cell activation and T-cell migration, we hypothesized that increasing EGFL7 levels after allo-HSCT will diminish the severity of aGVHD. Here, we show that treatment with recombinant EGFL7 (rEGFL7) in 2 different murine models of aGVHD decreases aGVHD severity and improves survival in recipient mice after allogeneic transplantation with respect to controls without affecting graft-versus-leukemia effect. Furthermore, we showed that rEGFL7 treatment results in higher thymocytes, T, B, and dendritic cell counts in recipient mice after allo-HSCT. This study constitutes a proof of concept of the ability of rEGFL7 therapy to reduce GHVD severity and mortality after allo-HSCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Dorrance AM, Moutuou MM, Goda C, et al. Modulating endothelial cells with EGFL7 to diminish aGVHD after allogeneic bone marrow transplantation in mice. Blood Adv. 2022. PMID: 34654057. doi:10.1182/bloodadvances.2021005498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。